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Abstract: Viruses employ an array of elaborate strategies to overcome plant defense 
mechanisms and must adapt to the requirements of the host translational systems. Pokeweed 
antiviral protein (PAP) from Phytolacca americana is a ribosome inactivating protein (RIP) 
and is an RNA N-glycosidase that removes specific purine residues from the sarcin/ricin 
(S/R) loop of large rRNA, arresting protein synthesis at the translocation step. PAP is thought 
to play an important role in the plant’s defense mechanism against foreign pathogens.  
This review focuses on the structure, function, and the relationship of PAP to other RIPs, 
discusses molecular aspects of PAP antiviral activity, the novel inhibition of this plant toxin 
by a virus counteraction—a peptide linked to the viral genome (VPg), and possible 
applications of RIP-conjugated immunotoxins in cancer therapeutics. 
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An evolutionary arms race between plants and their pathogens has shaped each other’s elaborate 
strategies for survival. Many plants produce toxic proteins that are thought to play a key role in their 
defense mechanisms against foreign pathogenic invaders. These anti-pathogenic protein toxins are 
known as ribosome inactivating proteins (RIPs). RIPs are broadly distributed throughout the kingdom 
of plants, fungi, and have been identified in several species of bacteria. High toxicity of the castor 
(Ricinus communis) and jequirity (Abrus precatorius) bean plants owe their detrimental physiological 
effects toward eukaryotic cells to these poisons and have been known since antiquity [1]. The deadliness 
of many RIPs has been explored by political and military organizations to design biological  
weaponry [2–4], many scientists to generate transgenic species of plants resistant to viral and fungal 
infections [5,6], numerous cancer researchers in production of immuno-conjugate therapeutics [7–9],  
as well as mystery writers to engage the readers [10]. RIPs are RNA N-glycosidases that inhibit advanced 
stages of protein synthesis by selectively modifying large rRNA molecules and deactivating ribosomes [11]. 
Other plants (e.g., common pokeweed—Phytolacca americana and common soapwart—Saponaria 
officinalis) produce pokeweed antiviral protein (PAP) [12] and saporin [13], respectively, with increased 
antiviral and antifungal activities. Presently, evidence for the lack of RIPs has been obtained solely for 
Arabidopsis thaliana, as this plant does not express detectible amounts of RIPs nor contains a sequence 
that encodes for any putative RIP in its genome [14]. Generally, RIPs being potent cellular toxins are 
exported out of the cell once they are synthesized, and localized within the cell wall matrix [15]. It is 
hypothesized that they gain access into the cytoplasm as the pathogen enters the cell, thus promoting 
their activity by impairing host ribosomes [16]. 
2. Pokeweed Antiviral Protein: One of a Number of Ribosome Inactivating Proteins 
2.1. Introduction to the Ribosome Inactivating Proteins 
The term “ribosome inactivating protein” came about before the structure and enzymatic activities of 
RIPs were realized. After the mechanism of action of RIPs on ribosomes became clear, the name is used 
for these N-glycosidases [EC 3.2.2.22]. Enzymes known as proteases and RNases inactivate or damage 
ribosomes by different mechanisms, and may not be classified as RIPs [17].  
2.1.1. Classification of Pokeweed Antiviral Protein among Other Ribosome Inactivating Proteins 
The first acknowledged RIPs were ricin and abrin [18,19]. However, only in 1971 ricin was 
recognized as an inhibitor of eukaryotic protein synthesis [20]. It was not established until several years 
later that the inhibition of protein synthesis was due to the impairment of host ribosomes [21]. PAP was 
also reported to impair protein synthesis through a related mechanism [22].  
Classification of RIPs into holo- and chimero-subgroups was founded on their physical properties, 
the number of polypeptide chains, and posttranslational modifications (Figure 1) [23,24]. Holo-RIPs, 
having a single RNA N-glycosidase domain, are frequently referred to as type 1 RIPs. These consist of 
a single intact polypeptide of ~30 kDa [12,25]. Type 1 RIPs are strongly basic proteins that are clearly 
distinct in their global sequence homology and posttranslational alterations, yet share several active site 
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residues and secondary structure elements [26–28]. Examples of type 1 RIPs include PAP, saporin, and 
barley (Hordeum vulgare) translational inhibitor. Type 1 RIPs inhibit cell-free protein synthesis and are 
only mildly toxic to cells and animals. The majority of characterized RIPs fall into this category [25]. 
Among type 1 RIPs, the 3D structures of saporin, momordin (MOM), PAP, trichosanthin and gelonin 
have been determined and their properties characterized [26,29–32]. Fifteen isoforms of saporin from  
S. officinalis have been characterized, differing in ribosome translation inhibition activities and cellular 
toxicity [33]. Crystal structure at 2.0 Å resolution of isoform 6 of saporin (SO6) has been reported with 
a structural motif that includes three lysyl residues in its C-terminal region—a highly conserved motif 
in all RIPs [29]. X-ray crystal structure of PAP has been determined [34] with various active site 
inhibitors and rRNA substrate analogues. Graphical Abstract presents a low temperature structure of 
PAP (PDB ID 1QCI). 
 
Figure 1. Schematic depiction of the structure of ribosome inactivating proteins (RIPs). 
Chimero-RIPs contain two structurally and functionally distinct domains: the catalytic RNA  
N-glycosidase domain and the carbohydrate (lectin properties) binding domain, and are better known as 
type 2 RIPs. Examples of these acutely toxic heterodimeric proteins include ricin, abrin and modeccin. 
Their amino-terminal domain is equivalent to the catalytic domain of type 1 RIPs—the RIP activity 
domain, often referred to as the A-chain (e.g., RTA—ricin A-chain). The catalytic domain is disulfide 
bridge-linked to an evolutionary divergent carboxyl-terminal B-chain, possessing sugar-binding 
properties of ~30 kDa [35–37]. Galactosyl moieties of glycoproteins and/or glycolipids, localized on the 
exterior of eukaryotic cells [38–40], are bound by the lectin chains of type 2 RIPs. This binding promotes 
the reverse transport of the A-chain to the cytosol [41–43]. Once inside the cell, the RIP accesses 
translational machinery and depurinates ribosomes. Extracellular location of RIPs prevents contact 
between these poisons and the ribosomes of healthy cells, yet provides an immediate source of the toxin 
when a pathogen infects the cell. The type 2 RIPs have proven to be invaluable for studies of endocytosis 
and intracellular transport into mammalian cells [44–46]. It is not clear how type 1 RIPs are distributed 
within the extra-cellular spaces of the host cells, although primary structure analysis points to fatty acid 
binding sequences within their sequences [15,47]. Clear evidence however, has been presented for PAP 
retro-translocation from the endoplasmic reticulum into the cytosol [48].  
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Type 3 RIPs are synthesized as inert precursors (pro-RIPs), and undergo proteolytic modifications to 
acquire their enzymatically activity [23]. These RIPs are much less common than either type 1 or  
type 2 RIPs. Type 3 RIPs have been identified from maize (Zea mays) and barley (from H. vulgare) [49–52].  
2.1.2. Distribution of Ribosome Inactivating Proteins 
RIPs are broadly dispersed among plants, fungi, alga, and several species of bacteria [25,53,54]. 
Additionally, RIP-type activity has been reported in animal tissues as well [55]. A large number of RIPs 
has been identified in a small group of families, namely Carylphyllaceae, Cucurbitaceae, Euphorbiaceae, 
Sambucaceae, Phytolaccaceae and Poaceae [24]. Synthesis of some RIPs could be induced by factors, 
such as senescence [56], viral infection [57], development [51] and stress [58].  
The molecular weight of type 1 RIPs ranges within 21–38 kDa. As for type 2 RIPs, the molecular 
weights of the two-chain peptide range from 56 to 69 kDa [24]. Bacterial RIPs Stx1 and Stx2 from 
Escherichia coli (E. coli) promote their enzymatic activity similar to their plant analogues [59–63]. 
Research reveals that RIPs are found in several fungi species [64–67]. At least one RIP has been isolated 
from alga, Laminaria japonica A. [68]. All of the above findings favor the generally accepted hypothesis 
that RIPs are enzymes widely distributed in nature, and therefore play pivotal undefined biological roles. 
Pokeweed Antiviral Protein and Its Isoforms 
Most type 1 RIPs are encoded by intron-less genes that define pro-RIPs with N- and C-terminal 
extensions with respect to the mature forms, e.g., several isoforms of pokeweed antiviral protein from 
P. americana have been described (Table 1) [12,24,69–71]. All of them possess pronounced antiviral 
properties and high enzymatic activity on ribosomes from diverse phyla. These isoforms are encoded by 
a gene family composed of approximately nine members [69]. PAPI (or simply PAP), PAP-II and  
PAP-III are the leaf isoforms that appear in spring, early and late summer, respectively [12,69–73], 
whereas PAP-S1 and PAP-S2 are the isoforms isolated from seeds and have been shown to exhibit the 
highest activity in vitro of all the isoforms [74–76]. PAP and PAP-S1 share 76% sequence identity,  
PAP-S1 and PAP-S2 have 83%, whereas PAP and PAP-II are only 33% identical [76,77]. A further 
isoform, α-PAP, is similar in sequence to PAP-S1, and essentially expressed in all organs [76,77];  
it shares 74% identity with PAP. PAP-R has been isolated from roots of the pokeweed plant [24,78] and 
PAP-H is from hairy roots [24,79]. Moreover, RIP-free callus and suspension cultures of P. americana 
have been attained [24,80]. Perhaps, a gene-silencing event occurred during the establishment of the 
cultures because RIP-isoforms are ubiquitously expressed in all organs of the plant [77].  
The genes of PAP [69], PAP-II [72] and PAP-S [81] have been isolated from tissue specific cDNA 
libraries and sequenced. The PAP gene carries an open reading frame of 939 nt coding for the mature 
PAP protein (262 amino acids) plus an N-terminal signal peptide of 22 amino acids [69] and a C-terminal 
extra peptide of 29 amino acids [30]. This gene has been expressed in E. coli cells under an inducible 
(lac) promoter with an extremely low yield (0.13%–0.16% of the total bacterial protein) [82]. It was 
found that even the low level of gene expression slowed down bacterial growth significantly.  
Chen et al., also found that elimination of N-terminal signal peptide codons (22 amino acids) from the 
PAP gene led to an immediate cell death [82]. The authors have concluded that PAP is highly toxic (in vivo) 
for prokaryotic cells [83]. Crystal structure of PAP-I, α-PAP, and PAP-II have been determined at 
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different resolutions [30,34,84]. PAP-S differs from other PAP isoforms; it is associated with three  
N-acetylglucosamine residues covalently attached to the protein’s asparagine residues [85]. Based on 
the X-ray and molecular modeling studies, PAP-III is predicted to have a greater anti-HIV activity due 
to its topology and charge distribution [86]. Moreover, modeling studies have indicated that PAP is able 
to accommodate a guanine base in its active pocket without large conformational changes, and this 
prediction was experimentally confirmed [87]. 





MW (kDa),  
Mature  
Protein 
Activity (RC50) References 
PAP-I Spring Leaves 262 29 
1.5 nM Rat Liver Ribosomes; 
4.7 nM E. coli Ribosomes 
[70]  
PAP-II Early Summer Leaves 285 30 ND [70]  
PAP-III Late Summer Leaves 285 30 ND [86,88] 
PAP-S1 Seeds 262 29 
3.2 nM Rat Liver Ribosomes; 
280 nM E. coli Ribosomes 
[75,76] 
PAP-S2 Seeds 262 29 
3.6 nM Rat Liver Ribosomes; 
1000 nM E. coli Ribosomes 
[75,76] 
α-PAP 
Expressed in  
All Organs 
261 28.9 
1.3 nM Rat Liver Ribosomes; 
25 nM E. coli Ribosomes 
[76]  
PAP-R Roots 271 29.8 ND [89]  
PAP-H Hairy Roots 268 29.5 ND [90]  
PAP-Culture Tissue Culture 262 29 ND [91]  
2.2. Biological and Enzymatic Activities of Ribosome Inactivating Proteins 
Distinct biological activity of both type 1 and type 2 RIPs has served as the basis for their identification. 
Type 2 RIPs owe their toxicity and cytotoxicity to the deviations in the lectin activity and specificity of 
the B-chain, and present with significant differences in their cytotoxicity. Ricin, for instance, is known 
to induce 50% apoptosis in cells at concentrations below 1 ng/mL, while some elderberry type 2 RIPs 
display no significant effects at 1 mg/mL [78].  
The inhibitory effect of PAP on tobacco mosaic virus (TMV) transmission was reported in 1925 by 
Duggar and Armstrong [79], yet PAP was not acknowledged as a protein synthesis inhibitor until 1978 [80]. 
Myriad type 1 RIPs are antiviral proteins. Type 1 RIPs are not as cytotoxic as type 2 RIPs, since they 
are not able to cross the cell membrane on their own. Nevertheless, a number of specialized animal cells 
are able to import type 1 RIPs by endocytosis, and consequently are susceptible to the RIP activity. 
Monomeric protein synthesis inhibitors share a significant sequence identity with ricin’s A-chain (RTA). 
Further, ricin, abrin, and PAP inhibit cell-free protein synthesis by permanent inactivation of the 
ribosomes by means of arresting the function of elongation factors EF-1 and EF-2 [25,92].  
It is well known that some RIPs possess multiple enzymatic activities. Some RIPs act on rRNA at 
specific single sites [93]; yet others were shown to depurinate multiple adenines from various nucleic 
acid substrates, such as herring sperm DNA, poly(A), tRNA, and even TMV RNA [94]. Site-specific 
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RNA N-glycosidase activity (Figure 2) toward ribosomes, rRNA, and depurination of mRNA and viral 
RNA are briefly discussed below.  
 
Figure 2. Schematic representation of the action sites for RNA N-glycosidase activity, 
polynucleotide:adenosine glycosidase (PAG) activity, and presumed DNase-like and 
phosphatase activity of RIPs. 
2.2.1. Site-Specific RNA N-Glycosidase Activity towards Ribosomes and Naked rRNA 
Ricin and other RIPs recognize a specific and universally conserved region within the large 28S rRNA, 
and cleave a glycosidic bond between an adenine and the nucleotide on the RNA [95]. For rat liver 
ribosome, this distinct site is A4324, and it is positioned within a single-stranded loop referred to as the 
sarcin/ricin (S/R) loop. The S/R loop is located within the domain VII of the 28S rRNA (Figure 3) [25,96]. 
After the adenine is removed, the depurinated site becomes subject to a β-elimination hydrolysis when 
treated with acidic aniline. This promotes cleavage of the 3'-end of the rRNA, and the depurination 
product can be detected by electrophoresis. This site-specific RNA N-glycosidase activity is a common 
characteristic attributed to all RIPs. Schramm et al., showed that the transition state of the ricin reaction 
develops an oxocarbenium character on the ribose [97]. Furthermore, it was established that RTA 
operates via a DN*AN mechanism [98]. This was further confirmed by the synthesis of novel compounds 
that incorporated the cationic character, such as amines, into a ribose analogue. As expected for true 
transition state analogues, these were potent, tightly binding, ricin inhibitors [98]. Tanaka et al., have 
used the RTA transition state knowledge to design and synthesize a high affinity inhibitor of the RTA 
catalytic site [98]. PAP and other RIPs inhibit the translocation step of elongation [99]. Specifically, 
PAP inhibits Ty1-directed +1 ribosomal frameshifting and retrotransposition [100,101].  




Figure 3. Structure of rRNA substrates for N-glycosidase activity of RIPs: (e) E. coli;  
(h) Homo sapiens; (m) Mus musculus; (o) Oryza sativa; (r) Rattus rattus;  
(s) Saccharomyces cerevisiae; (x) Xenopus laevis. 
The S/R loop within the rRNA of different ribosomes is universally conserved across all species 
(Figure 3) [24]. Consequently, the specificity of different RIPs for their substrates, and the sensitivity 
between ribosomes among species are likely to come from deviations within RIPs themselves and the 
ribosomal proteins. Ricin presents highest activity toward yeast and mammalian ribosomes, but exhibits 
low activity on plant and E. coli ribosomes [25], whereas PAP depurinates ribosomes from plants, 
bacteria, yeasts, and lower and higher animals [25]. RIP substrate accessibility may be influenced by the 
deviations in ribosomal proteins that would dictate RIP activity and sensitivity towards different 
ribosomes. The L9 and L10e rat liver ribosomal proteins are targeted by the ricin A chain (RTA) [102], 
however PAP has been shown to bind to the L3 yeast ribosomal protein [103,104]. Transgenic plants, 
expressing truncated L3 ribosomal protein, confer resistance to PAP [104]. Furthermore, broad-spectrum 
activity of PAP towards different ribosomes may be explained by the fact that the L3 ribosomal protein 
is highly conserved. Pokeweed ribosomes were shown to be as sensitive to PAP treatment as wheat 
ribosomes [16]. The rRNA in native ribosomes is the ideal substrate for RIPs, nonetheless, protein-free 
rRNA [105] and synthetic oligoribonucleotides that mimic the S/R domain [106,107], serve as substrates 
for RIP activity as well. All RIP depurinate the equivalent adenine residue from naked rRNA as from 
native ribosomes, but many of them depurinate naked rRNA at multiple sites. In addition, several RIPs 
are able to depurinate naked rRNA from non-substrate ribosomes. For instance, ricin is able to act on 
naked E. coli 23S rRNA, however possesses no activity against the intact E. coli ribosomes. Moreover, 
several RIPs are able of depurinating guanine residues within their substrates [34,108]. 
2.2.2. Depurination of Capped and Uncapped mRNA; Antiviral Action of PAP 
Advances in high-performance liquid chromatography (HPLC) coupled to fluorescent methods of 
detection, allowed researchers to detect, identify, and quantify possible reaction products of RIPs and 
the amount of free adenine released from different substrates by RIPs [107,109]. These techniques allow 
for direct measurement of ribosomal depurination, quantification of released purines, and also aided in 
identification of some uncommon activities of RIPs. For instance, various RIPs serve as effective 
inhibitors of animal and/or plant viruses. Depurination of viral RNA by RIPs is a novel activity, and any 
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insights into the mechanism of substrate selectivity and specificity may be of paramount importance in 
the search for the potent antiviral agents. The mode of action for the antiviral activity of RIPs is poorly 
understood, however this activity does not depend solely on the ribosomal inactivation. An alternative 
mechanism may involve a direct interaction of RIP with viral RNA or DNA, with additional effects 
brought about by the eukaryotic translation initiation factors (eIFs). Pokeweed antiviral proteins PAP-I, 
PAP-II, and PAP-III cause a concentration-dependent depurination of genomic HIV-1 RNA [88,110,111], 
TMV RNA [112], poliovirus [113], herpes simplex virus [114], influenza virus [115], brome mosaic virus 
(BMV) [116], lymphocytic choriomeningitis virus (LCMV) [117], tobacco etch virus (TEV) RNA [107], 
and inhibits Japanese encephalitis virus infection, both in vitro and in vivo [118]. In contrast, the RTA 
does not depurinate same viral RNAs to produce detectable quantities of purines. 
A novel mechanism for the inhibition of translation by PAP has been put forward [119]. This 
inhibition of translation is based on a specific depurination of capped mRNA. Hudak et al., used wild 
type (WT) PAP and three different PAP mutants (PAPx, an active site mutant (E176V); PAPn, a mutant 
with a substitution (G75D) in the amino-terminal sequence; PAPc, a mutant lacking the carboxyl-terminal 
25 amino acid residues) that do not depurinate tobacco or rabbit ribosomes, and have shown that PAP 
inhibits the in vitro translation of BMV and potato virus X RNAs without ribosomal depurination [119]. 
This shows that PAP is able to differentiate between capped and uncapped mRNAs, since PAP, and 
some of its mutants, inhibited the translation of capped (but not uncapped) luciferase transcripts. 
Presence of m7GTP analogue lowers translational inactivation activity of PAP and PAP mutants, 
implying that these RIPs are able to recognize the cap structure on the mRNAs [120]. PAP-treated 
luciferase transcripts revealed that the capped, but not the uncapped RNAs were subject to degradation 
by acidic aniline, and therefore were depurinated in vitro. It was concluded that PAP may inhibit 
translation by binding to the cap structure and depurinating the RNA, and that depurination of capped 
viral RNA may be the principal mechanism for the antiviral activity of PAP [120]. Baldwin et al. [121] 
have characterized the interactions of PAP with m7GTP cap analogue using fluorescence spectroscopy, 
and these interactions were previously identified as competitive [107]. Zoubenko et al., have presented 
evidence that PAP depurinates tobacco ribosomes in vivo by removing more than one adenine and a 
guanine [122]. Moreover, PAPn mutant did not bind ribosomes efficiently pointing to the importance of 
Gly-75 for PAP to bind ribosomes. Unlike wild type PAP (or the C-terminal PAPC mutant), PAPn did 
not trigger production of salicylic acid in transgenic plants [122]. 
These results depict a promising mechanism to explain the antiviral activity of PAP, however, some 
queries remain. For instance, the above-proposed mechanism does not clarify the inhibitory effect of PAP 
on the replication of uncapped viruses such as influenza [115] and poliovirus [113]. Vivanco et al., [123] 
have examined the activity of PAP against a variety of capped and uncapped viral RNAs, and 
demonstrated that PAP does not depurinate every capped RNA, and that it can inhibit translation of 
uncapped viral RNAs in vitro without causing detectable depurination. PAP depurinated the capped 
TMV and BMV RNAs, but did not depurinate the uncapped luciferase RNA, indicating that PAP can 
distinguish between capped and uncapped RNAs, but no detectable depurination of capped alfalfa 
mosaic virus (AMV) RNA was recorded. This implies that recognition of the cap structure alone is not 
sufficient for depurination of RNAs [123]. Moreover, PAP did not cause detectable depurination of 
uncapped RNAs from tomato bushy stunt virus (TBSV), satellite panicum mosaic virus (SPMV), and 
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uncapped RNA containing poliovirus IRES (internal ribosome entry site); however, in vitro translation 
experiments showed that PAP inhibited translation of the above viral RNAs [123].  
2.2.3. Effects of eIFs and RNA Secondary Structure—Missing Links in PAP-Substrate Selectivity 
Wang et al. [124] presented evidence that PAP binds to eIF4G and its isoform eIFiso4G. In wheat 
(Triticum aestivum), two forms of eIF4G exist, which differ in size, 180 (eIF4G) and 86 kDa (eIFiso4G), 
and they bear only 30% amino acid identity [125,126]. PAP binds to m7GTP-Sepharose and this 
interaction does not diminish the binding of PAP to purified eIFiso4G, indicating that a complex can 
form between the cap structure, PAP and eIFiso4G. In the presence of wheat germ lysate, PAP 
depurinated uncapped transcripts having a functional WT 3'translational enhancer sequence (3'TE), but 
did not depurinate messages containing a non-functional mutant 3'TE [124]. This result supports earlier 
hypothesis that binding of PAP to eIF4G and eIFiso4G could provide a mechanism for PAP to access both 
uncapped and capped viral RNAs for depurination. In support to the above findings, Baldwin et al. [121] 
have shown that PAP not only binds to the initiation factor scaffolding protein eIFiso4G, but that binding 
of cap analogue to PAP is increased by these protein-protein interactions, suggesting a model where 
PAP interacts with eIFiso4G/eIF4G (as part of the eIFiso4F/eIF4F complex) and binds to the cap region 
of mRNA. Furthermore, addition of eIFiso4E/eIF4E (as part of the eIFiso4F/eIF4F complex) lowers the 
binding affinity of PAP for the cap competitively because both are specific cap-binding proteins.  
The ability of PAP to lower infectivity of both capped and uncapped RNA viruses suggests the presence 
of a different, other than m7G cap, requirement that may influence PAP substrate recognition, binding, 
and its antiviral activity. This was further supported by the pull-down assay and the Fluorescence 
Resonance Energy Transfer (FRET) experiments, where Cheng et al. showed that the formation of a 
triplex complex between PAP, eIFiso4E and eIFiso4G dramatically increase FRET energy transfer upon 
binding of the eIFiso4G to the binary PAP-eIFiso4E complex [127]. This triplex protein interaction 
demonstrates that eIFiso4G plays a key role in the regulation of PAP binding.  
Elements within RNA secondary structures have been identified to play differentiated roles in PAP 
binding to various structured RNAs. The 3'-UTRs of the non-polyadenylated plant viral mRNAs of TMV 
and BMV are known to increase both the stability and the translational efficiency of a message [128,129] 
in carrot protoplasts, whereas those of turnip mosaic (TYMV) and AMV viruses show no (or lowered) 
effect on gene expression [129]. PAP depurinating activity on these structural viral RNAs correlates to 
the 3'-UTRs translational effect [130]. Moreover, the presence of the eIFs reveal drastic differences in 
the activity of PAP for its viral substrates, in a way that eIFiso4F (complex of eIFiso4E and eIFiso4G) 
promotes increased affinity (and activity) of PAP for the TMV and BMV RNAs, whereas there is a 
negligible effect of eIFiso4F on the binding to the TYMV and AMV, and no profound effect on the 
depurination of the these RNAs [131]. These PAP-eIF-RNA interactions possibly promote PAP active 
site structural changes, allowing PAP to recognize purine residues for depurination. 
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2.3. Physiological Role, Toxicity of RIPs and Immunotoxins 
2.3.1. Physiological Role of RIPs 
Presently, there is no unequivocal and agreeable answer to why plants produce and accumulate RIPs, 
despite the comprehensive knowledge of their structure, activity, and action mechanism. RIPs are 
synthesized in many, but not all, plant species. Sequencing of the genome of A. thaliana provided no 
evidence of RIP encoding genes [14]. This suggests that RIPs are not ubiquitous among plant species, 
and do not play a universal role in their growth, development, or defense. Some facts support the notion 
that RIPs play a defense function in plants. Only type 2 RIPs are able to gain entree to the cytoplasm of 
intact cells via a receptor-lectin-mediated uptake process [25,132]. Toxicity of type 2 RIPs is restricted 
to animal cells because bacteria and fungi are protected by a cell wall; type 2 RIPs they must bind glycan 
receptors on the cell surface to ensure their entry. Ricin and abrin are thought to protect the seeds of 
these plants against plant-eating animals [133]. Type 1 RIPs have direct effect on yeast and plant 
pathogenic fungi [134]. Recent studies show that transgenic tobacco plant lines (Nicotiana tabacum), 
expressing an activated form of maize (Z. mays), a type 3 RIP, appear more resistant to larvae of the 
cigarette beetle (Lasioderma Serricorne) and the tobacco hornworm (Manduca Sexta) than the wild type 
plants [135], providing a resistance to these maize-eating insects. Presently though, there is no 
documented oral toxicity of type 1 and 3 RIPs on higher animals. RIPs possess a set of unique biological 
activities toward human and animal cells that could be exploited in antiviral drug therapeutics.  
The antiviral activity of type 1 RIPs is well documented [136], although the underlying mechanism has 
not been elucidated.  
2.3.2. Toxicity of Ribosome Inactivating Proteins 
Reports about the use of ricin and abrin for homicidal purposes go back to ancient times. Nonetheless, 
usage of these toxins as regular weapons is a quite modern idea. The ease to acquire large amount of 
ricin, for example, made this toxin a good candidate for bioterrorism.  
In 1952 the US Army filed a patent on how to prepare ricin for weapon purposes [137]. Certainly the 
extent to which ricin was collected for military purposes is not known. It was, however, intended to be 
employed in assassination of Georgi Markov and Vladimir Kostov, exiled journalists who published 
incriminate information about the corrupt life of the Bulgarian communist leadership [1,3]. Five more 
instances were identified where this assassination technique was used. In the past decade ricin has been 
associated with terrorist organizations in several countries. The availability of improved anti-ricin 
vaccine [138] and better ability to trace and identify toxin in the body should make the toxin a less 
tempting compound for use in bioterrorism [1,139]. 
In 2013, CNN Justice [140] has reported that the Texas actress, Shannon G. Richardson, was 
sentenced to 18 years in prison after admitting last year that she sent ricin-tainted letters to the US 
President Barack Obama and then New York City Mayor Michael Bloomberg. 
Type 1 RIPs are certainly not as cytotoxic to higher animals, since they cannot cross the cell 
membrane on their own [16]. Pokeweed plant synthesizes its toxin as a precursor and compartmentalizes 
it within cell wall matrix [15]. This ensures that the pokeweed’s ribosomes never encounter its own 
toxin, leaving overall protein synthesis unaffected. In contrast to the healthy appearance of pokeweed, 
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the expression of PAP in transgenic N. tabacum plants leads to various physiological changes [5]. 
Transgenic tobacco plants producing high levels (more than 10 ng/mg protein) of PAP were sterile, 
having a stunted, molted phenotype. This correlated with the level of PAP expressed. Plants producing 
less than 1–5 ng PAP/mg protein were fertile and normal in appearance [5,134]. In recent studies,  
Hudak et al., have shown PAP undergoing homodimerization as a mechanism to limit depurination of 
pokeweed ribosomes [141]. 
2.3.3. Immunotoxins and Other Conjugates of RIPs 
The first carrier-toxin hetero-conjugates of RIPs were prepared using polyclonal and later monoclonal 
antibodies with toxins that were able to block protein synthesis at the ribosome level. Bio-specific agents 
other than monoclonal antibodies (hormones, growth factors, antigens, cytokines, etc.) have also been 
employed in developing cell-targeting conjugates [142]. Toxins of different types can be used to 
construct effective immunotoxin (IT) conjugates, including plant, bacterial and fungal toxins. RIPs [54] 
have been extensively used in preparation of such ITs. These chimeric ITs can be made with either  
type 1 or type 2 RIPs [143]. The linkage of the carrier molecule to the toxin can be attained by chemical 
cross-linking, indirect linking, or gene fusion [144]. 
Several lines of research have efficiently used PAP as a component of ITs, conjugated to a variety of 
monoclonal antibodies. Jansen et al. [145] have used B43-PAP immunotoxin plus cyclophosphamide to 
successfully treat human leukemia in mice with severe combined immunodeficiency (SCID).  
Uckun et al., have used B43 (anti-CD19)-PAP IT in treatment of human pre-B acute lymphoblastic and 
other types of leukemia in mice [146–149]. Erice et al. [150] have found that PAP conjugated to 
monoclonal antibodies recognizing CD4, CD5, or CD7 antigens effectively inhibited HIV-1 replication 
in normal CD4+ T cells infected with HIV-1 strain LAVBRU, as well as in activated T cells from two 
asymptomatic HIV-1-seropositive individuals [151]. All of the above and many other lines of evidence 
point toward potential therapeutic PAP-immunoconjugate applications of this protein against a variety 
of cancer lines as well as HIV-1. 
Liposomal delivery of RIPs may provide both hydrophilic, hydrophobic environments, enhancing 
RIP solubility. It uses regulated drug release, and thus reduces or eliminates tissue damage on accidental 
extravasation, and protects RIP from premature degradation, functions as a sustained release system, and 
can substantially alter the pharmacokinetics of the RIP and reduce clearance [152]. As all of the above 
properties of targeted liposomal employment of RIPs become surmounted, RIP-conjugated 
immunotoxins may become an important new modality for cancer therapy. The major dose-limiting 
toxicity of RIP-conjugated immunotoxin therapies is vascular leak syndrome (VLS) [153]. VLS is 
characterized by an increase in vascular permeability accompanied by extravasation of fluids and 
proteins resulting in interstitial edema and organ failure. 
2.3.4. Interactions of PAP with VPg and the Inhibition of PAP Antiviral Activity 
Researchers have undertaken extensive efforts in exploration of RIP properties and studies of their 
toxicities in order to develop antidotes against their activity. Biochemical and structural characterization 
of the catalytic domains of many RIPs, including RTA, served as an attractive target for structure-based 
drug design. Our comprehension of the RIP action mechanism predominantly comes from the structural 
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and mutagenesis work [154,155]. Advances in the X-ray crystallography allowed for the determination 
of the high-resolution structures of RIP catalytic domains, and thus development of substrate analogues 
that possess high affinity for the RIP active sites. Several categories of RIP inhibitors have been 
developed. Thus far, effective small molecule RTA inhibitors are generally based on pterins, guanines, 
pyrimidines, and stem-loop oligonucleotides. Schramm and his colleagues have developed transition 
state analogues that have high affinities for the RTA active site; these however, only bind at acidic pH, 
around 4 [97,98]. In recent years, RIP activity of PAP was shown to be inhibited by a viral  
peptide—genome-linked protein, VPg isolated from the turnip mosaic potyvirus (TuMV) [107]. High 
affinity of the viral peptide for PAP (Kd = 29 nM), and its ability to inhibit PAP enzymatic activity, 
provides a new direction in search for a novel generation of RIP inhibitors.  
The genus Potyvirus contains more than 200 members and belongs to one of the largest plant virus 
family—Potyviridae [156]. Potyviruses contain an approximately 10 kilobases positive-sense ssRNA 
that is covalently linked to a viral genome-linked protein (VPg) at their 5' end via a tyrosine residue [157] 
and polyadenylated at the 3'end [158–160]. The RNA has a single open reading frame that is translated 
into a large polyprotein. The potyviral polyprotein is proteolytically processed into mature proteins by 
dedicated virus-encoded proteases [161]. It has been suggested that VPg may serve as an analogue of 
the m7G cap of the mRNAs, and plays a role in mRNA translation because of its interactions with the 
cap-binding eIF4E (eIFiso4E) and eIF4F (eIFiso4F) proteins [162,163]. Studies also support a biological 
role for the VPg linked to the viral RNA in virions. VPg is necessary for the infectivity of the virus [164], 
cell-to-cell movement [165–170], and has been linked to a variety of other viral necessities. 
Interactions between PAP and VPg were studied over a range of different temperatures using direct 
fluorescence titrations. These interactions were recognized as competitive [107], because VPg competed 
with the TEV RNA for PAP binding. Thermodynamics of the PAP-VPg binding were identified as 
enthalpically driven and entropically favorable [107], and exhibited similarities to those of eIFiso4E- and 
eIFiso4F-VPg binding [163]. Nearly one-third contribution from the TΔS van’t Hoff component to the 
overall energy suggests that these interactions are driven by structural changes in both proteins, in a way 
where hydrophobic residues become less solvent exposed. In addition, PAP showed greater affinity for 
the viral peptide, as compared to m7GTP-cap analogue [121] and eIFiso4F [163]. Greater affinity of PAP 
for VPg than that for the cap structure would produce an advantage for the cell if VPg were to localize 
PAP to viral RNA for depurination. Beguilingly, VPg inhibited PAP activity by decreasing the mounts 
of purines released from various RNAs [107], suggesting that it may participate in viral strategy to 
overcome one of the potential host cell defense mechanisms. This is further supported Baldwin et al. [121], 
and conforms to the accepted function of PAP as a RIP. Although there are suggested similarities in the 
thermodynamics of PAP-VPg interactions with the eIF binding, different equilibrium dissociation 
constant values point toward the differences in the active sites of PAP and the cap-binding sites of the 
initiation factors.  
4. Conclusions 
Exploitation of RIPs as potential targets in bioterrorism, and their usage as possible antiviral and  
anti-cancer agents deserve further attention. Cytotoxicity of RIPs and their effects on biological systems 
present the investigators with novel ideas in exploration of new pathways for the inhibition of RIP 
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activity, as well as modulation of the current inhibitors to perfect their action. These inhibitors may even 
assist in controlling non-specific cytotoxicity of RIP-immunoconjugates, and serve as antidotes against 
their toxicity. Recently, there has been an interest in structure-based drug design that uses the knowledge 
of protein structure and its ligand interactions to identify potent enzyme inhibitors. The X-ray crystal 
structures of ricin, PAP and other RIPs have been solved, and the presence of various substrate analogs 
interacting with RTA side chain amino acids has been mapped out [28,30,171], identifying pivotal 
residues for catalysis [172]. Kurinov et al., have reported crystal structures of PAP co-crystallized with 
adenyl-guanosine (ApG) and adenyl-cytosine-cytosine (ApCpC), and showed evidence for a broad 
spectrum N-glycosidase activity of PAP toward adenine-containing single stranded RNA [34]. The 
inhibitory action of VPg on RIPs has not been studied in great detail, and may present researchers with 
new insights in understanding not only the inhibitory mechanism of PAP and other RIPs, but also a 
deeper insight into an evolutionary adaptation of plant-virus interactions, and a new direction in 
understanding how these plant-pathogen relations have shaped each other for generations. Khan et al., 
have shown that VPg may serve as a cap analog [162,163], and stimulates the in vitro translation of 
uncapped IRES-containing RNA to promote viral gene translation [173]. In addition, VPg inhibits 
cellular capped RNA translation in wheat germ extract by recruiting the translation initiation factors  
(4E and iso4E) [173]. The central domain of potyviral VPg is involved in the interactions with the eIF [174], 
and alterations within VPg structure abolish these interactions [159]. The N-terminal truncation renders 
VPg unable to interact with the eIF4E and eIFiso4E [159], and the binding site on VPg for the eIFs 
overlaps with that for PAP binding [107]. PAP may therefore have antiviral activity both through 
ribosome inactivation and RNA depurination as well as binding to VPg and potentially sequestering it. 
VPg is essential for viral replication and this may be a new role for PAP in antiviral defense. Future 
investigations of the inhibitory effects of VPg on other RIP activity may provide researchers with a novel 
and natural peptide inhibitors of the cytotoxic activity of RIPs. This novel peptide inhibitor may aid in 
non-specific inhibition of RIP activity when used as immunoconjugates in anti-cancer of anti-viral 
regiments. RIP immunotoxins constitute a new modality for the treatment of cancer, since they target 
cells displaying specific surface-receptors and antigens. These chimeric proteins consisting of an 
antibody linked to a toxin. The antibody confers specificity (ability to recognize and react with the target), 
whereas the toxin confers cytotoxicity (ability to kill the target cell) [175,176]. Immunotoxins have been used 
in both mice and humans to eliminate tumor cells, autoimmune cells, and virus-infected cells [177–179].  
For instance, Uckun et al., have successfully used PAP conjugated to TP-3, an IgG2b mAb that 
recognizes human and canine osteosarcomas and budding capillaries of tumors, to lower the viability of 
human OHS osteosarcoma cells [180,181]. However, many obstacles arise from using RIPs as 
immunotoxins. Examples include, but not limited to, tissue damage on extravasation, rapid breakdown 
in vivo, unfavorable pharmacokinetics, poor biodistribution, and lack of selectivity for target  
tissues [152,181,182]. Immunoconjugates encapsulated into liposomes may alleviate these problems, 
and have been successfully used in the past for treatment of many types of cancers [183,184]. 
Immunoconjugated liposomal PAP may provide a new and promising direction in cancer therapeutics, 
and alleviate the above obstacles in cancer treatments.  
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